Aktiesnakken — November 2009
-
men ærligt Solsen, ingen analytiker med respekt for sig selv vil lave sådan en discountrate, det giver nada mening
-
25 mill for egfr!!! er de sindssyge for et kræftstof igennem fase 3!!!
-
vi fik 2 mia dollar for Arzerra efter fase 2!!!
-
jeg skriver faneme en bog om det her
-
jeg er rasende!
-
ja de skal have noget lede tørre tørre salgstal....tænk at 80% vil behandle med arzerra i RA!!!
-
ja det var dejligt tak
-
mit blodtryk har det dårligt
-
Fiona anbefaler: http://bis.0725.dk/pdf/20091111Anbefalingsliste.pdf
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind